Lipid profiles of people with human immunodeficiency virus with dyslipidemia after switching from efavirenz to dolutegravir

INTRODUCTION: Human immunodeficiency virus (HIV) infection and the long-term use of antiretroviral therapy, especially efavirenz (EFV)-based regimens, impact lipid profiles due to insulin resistance and lead to a higher risk of metabolic diseases. Dolutegravir (DTG) is an integrase inhibitor with be...

Descripción completa

Detalles Bibliográficos
Autores principales: Khemla, Supphachoke, Meesing, Atibordee, Sribenjalux, Wantin, Chetchotisakd, Ploenchan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AboutScience 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158613/
https://www.ncbi.nlm.nih.gov/pubmed/37153647
http://dx.doi.org/10.33393/dti.2023.2529

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158613/
https://www.ncbi.nlm.nih.gov/pubmed/37153647
http://dx.doi.org/10.33393/dti.2023.2529

Ejemplares similares